Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma

Condition:   Sarcoma Interventions:   Drug: Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC];   Drug: Nivolumab IV Soln 100 MG/10ML;   Drug: Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution Sponsor:   Sarcoma Oncology Research Center, LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials